For anyone in Peka looking to source CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. This matters because CJC-1295 quality ranges widely across the market — from verified research-grade material to products with serious contamination — and the vendor controls every quality variable. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for safety screening. Use this guide to evaluate CJC-1295 vendors rigorously — the standards covered in this guide work regardless of your location.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Peka comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Before looking at individual vendors, understand what genuine quality documentation contains — so you can identify whether a supplier meets the standard. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. The combination of community consensus and independent COA review is the most effective quality filter — community feedback surfaces patterns individual COA review misses, and vice versa. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Peka
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bacteriostatic water. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
